Exploring High Growth Tech Stocks In The US Market March 2026

Simply Wall St.03-27

Over the last 7 days, the United States market has experienced a 1.6% drop, yet it has shown resilience with a 15% increase over the past year and expectations for earnings to grow by 16% annually in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622823238?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-27 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622823238","market":"nz","top_or_hot":-1,"title":"Exploring High Growth Tech Stocks In The US Market March 2026","media":"Simply Wall St.","content":"<div>\n<p>Over the last 7 days, the United States market has experienced a 1.6% drop, yet it has shown resilience with a 15% increase over the past year and expectations for earnings to grow by 16% annually in ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/exploring-high-growth-tech-stocks-in-the-us-market-march-202-2\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exploring High Growth Tech Stocks In The US Market March 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExploring High Growth Tech Stocks In The US Market March 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-27 19:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/exploring-high-growth-tech-stocks-in-the-us-market-march-202-2><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the last 7 days, the United States market has experienced a 1.6% drop, yet it has shown resilience with a 15% increase over the past year and expectations for earnings to grow by 16% annually in ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/exploring-high-growth-tech-stocks-in-the-us-market-march-202-2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0002270589.USD","symbol_name":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/exploring-high-growth-tech-stocks-in-the-us-market-march-202-2","article_id":"2622823238","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/exploring-high-growth-tech-stocks-in-the-us-market-march-202-2","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622823238","pubTimestamp":1774609703,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Over the last 7 days, the United States market has experienced a 1.6% drop, yet it has shown resilience with a 15% increase over the past year and expectations for earnings to grow by 16% annually in the coming years. In this context of fluctuating short-term performance but promising long-term growth prospects, identifying high growth tech stocks that can capitalize on these trends becomes essential for investors seeking potential opportunities.","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BMRN":"拜玛林制药","BK4613":"AI应用软件","BK4023":"应用软件","BK4505":"高瓴资本持仓","BK4139":"生物科技","KVYO":"Klaviyo, Inc.","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","KNSA":"Kiniksa Pharmaceuticals Ltd.","BK4566":"资本集团"},"translate_title":"探索美国市场的高增长科技股2026年3月","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN":1,"KVYO":1,"KNSA":1},"content_text":"Over the last 7 days, the United States market has experienced a 1.6% drop, yet it has shown resilience with a 15% increase over the past year and expectations for earnings to grow by 16% annually in the coming years. In this context of fluctuating short-term performance but promising long-term growth prospects, identifying high growth tech stocks that can capitalize on these trends becomes essential for investors seeking potential opportunities.AdvertisementTop 10 High Growth Tech Companies In The United StatesNameRevenue GrowthEarnings GrowthGrowth RatingMarker Therapeutics61.33%65.71%★★★★★★Palantir Technologies27.02%31.25%★★★★★★Sandisk30.23%46.19%★★★★★★Reddit22.20%27.96%★★★★★★Gorilla Technology Group54.35%95.02%★★★★★☆Tenaya Therapeutics58.52%60.10%★★★★★☆Zscaler15.93%48.88%★★★★★☆Duos Technologies Group53.76%155.11%★★★★★☆Procore Technologies12.08%99.98%★★★★★☆KVH Industries25.44%135.75%★★★★★☆Click here to see the full list of 73 stocks from our US High Growth Tech and AI Stocks screener.Underneath we present a selection of stocks filtered out by our screen.BioMarin Pharmaceutical (BMRN)Simply Wall St Growth Rating: ★★★★☆☆Overview: BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for life-threatening rare diseases and medical conditions globally, with a market cap of approximately $10.69 billion.Operations: BioMarin Pharmaceutical generates revenue primarily from the development and commercialization of innovative therapies, amounting to $3.22 billion. The company operates across various international markets, focusing on life-threatening rare diseases and medical conditions.BioMarin Pharmaceutical, despite a challenging year with a 18.3% decline in earnings, is poised for recovery with expected annual earnings growth of 27.4%, outpacing the US market forecast of 15.6%. The firm's commitment to innovation is evident from its significant R&D investment, aligning with a revenue increase to $3.22 billion from $2.85 billion previously. Recent FDA approvals and positive trial outcomes for VOXZOGO suggest resilience and potential growth in its specialized therapeutic segments, although recent discontinuations in other trials underscore the risks inherent in biotech development.Take a closer look at BioMarin Pharmaceutical's potential here in our health report.Gain insights into BioMarin Pharmaceutical's past trends and performance with our Past report.BMRN Earnings and Revenue Growth as at Mar 2026Kiniksa Pharmaceuticals International (KNSA)Simply Wall St Growth Rating: ★★★★★☆Overview: Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing medical therapies across the United States, the United Kingdom, and internationally, with a market cap of approximately $3.51 billion.Operations: Kiniksa Pharmaceuticals generates revenue primarily from developing and delivering therapeutic medicines, amounting to $677.56 million. The company operates within the biopharmaceutical sector, focusing on medical therapies across various international markets.Kiniksa Pharmaceuticals International has demonstrated a notable turnaround, transitioning from a net loss to reporting a net income of $59.01 million in the recent fiscal year, up from a previous loss of $43.19 million. This financial recovery is underscored by an impressive annual revenue jump to $677.56 million, marking an increase from $423.24 million, reflecting robust growth and operational efficiency improvements under new executive leadership with strategic focuses including AI initiatives. The firm's R&D commitment remains strong, vital for sustaining innovation and competitive edge in the biotech landscape.Click here and access our complete health analysis report to understand the dynamics of Kiniksa Pharmaceuticals International.Explore historical data to track Kiniksa Pharmaceuticals International's performance over time in our Past section.KNSA Revenue and Expenses Breakdown as at Mar 2026Klaviyo (KVYO)Simply Wall St Growth Rating: ★★★★★☆Overview: Klaviyo, Inc. offers a cloud-based software-as-a-service platform across various regions including the United States, Asia-Pacific, and Europe, with a market cap of $5.53 billion.Operations: Klaviyo generates revenue primarily from its Internet Software segment, totaling $1.23 billion.Klaviyo, amidst a transformative phase in tech, has shown robust financial and innovative prowess. With an annual revenue growth of 16.2% and earnings poised to surge by 81.7% annually, the company's strategic focus on R&D is evident from its recent launch of Composer and expansion into AI-driven marketing solutions. These initiatives are supported by a substantial $500 million share repurchase program, underscoring confidence in its trajectory. Moreover, Klaviyo's deepened integration with Shopify highlights its commitment to enhancing global brand services through advanced CRM capabilities, setting a strong foundation for sustained growth in the dynamic digital marketing sector.Click to explore a detailed breakdown of our findings in Klaviyo's health report.Review our historical performance report to gain insights into Klaviyo's's past performance.KVYO Earnings and Revenue Growth as at Mar 2026Next StepsExplore the 73 names from our US High Growth Tech and AI Stocks screener here.Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.Ready To Venture Into Other Investment Styles?Explore high-performing small cap companies that haven't yet garnered significant analyst attention.Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.Find companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data \n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your \n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data. \n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. \n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Klaviyo might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622823238","isCrawlerRequest":true}